Summit gains as Citigroup raises to 'buy' on cancer drug prospects
ReutersMar 26, 2025 12:19 PM
Drug developer Summit Therapeutics' SMMT.O shares rise 4.9% to $21.23 premarket
Citigroup upgrades to "buy" from "neutral" citing strong confidence in HARMONi-2 trial for cancer drug ivonescimab, with chance of favorable results by end of 2025
Last month, co announced a collaboration with Pfizer PFE.N to study ivonescimab in combination with Pfizer's antibody drug conjugates (ADCs) across various tumor types
Brokerage says trial success could make ivonescimab a groundbreaking therapy in NSCLC (non-small cell lung cancer)
$35 PT for Summit represents ~53% upside to last close
Analysts' average rating is equivalent of "buy"; median PT $44 - data compiled by LSEG
Shares rose 13.4% YTD vs 12.5% increase in S&P 500 biotechnology index .SPLRCTKBI
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
National Debt Bomb Ignited? Musk Warns U.S. Will Be 1000% Bankrupt Without AI
TradingKey - Tesla (TSLA) CEO Elon Musk recently issued another warning regarding the rapidly ballooning U.S. national debt. He stated clearly that without artificial intelligence and robotics, the United States will inevitably head toward fiscal bankruptcy.TradingKey
11 hours ago
Tesla Stock Outlook: Competing With Rivian, Robotaxi Potential, and 2026 Prospects
There is much conversation about the prospect of investing in Tesla (TSLA) as we move closer to 2026. The volatility of its share price in 2025 is leading many investors to consider if they should purchase shares of Tesla given the alternatives available in terms of electric vehicles (Rivian, etc.).TradingKey
11 hours ago
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
Is Bitcoin’s Four-Year Cycle Dead in 2026?
Is the Bitcoin 4-year cycle dead? After 2025 broke historical records with a red post-halving year, institutional analysts explore if the Bitcoin price has decoupled from the halving countdown. Analyze the impact of spot ETFs, global liquidity, and the roadmap to the 2028 halving in this 2026 marketTradingKey
Wed, Feb 4
